In vitro and in vivo assessment of heart-homing porous silicon nanoparticles

Biomaterials

Volumn 94, Issue , 2016, Pages 93-104

  Ferreira, Mónica P A ^a   Ranjan, Sanjeev ^a   Correia, Alexandra M R ^a   Mäkilä, Ermei M ^b   Kinnunen, Sini M ^a   Zhang, Hongbo ^a,c   Shahbazi, Mohammad Ali ^a   Almeida, Patrick V ^a   Salonen, Jarno J ^b   Ruskoaho, Heikki J ^a   Airaksinen, Anu J ^a   Hirvonen, Jouni T ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Heart; In vivo; Myocardial infarction; Nanoparticles; Porous silicon; Targeting peptides

Indexed keywords

CARDIOLOGY; DISEASE CONTROL; DISEASES; HEART; NANOPARTICLES; PEPTIDES; SILICON; TOXICITY;

ATRIAL NATRIURETIC PEPTIDES; CHRONIC HEART FAILURES; FUTURE APPLICATIONS; GUANYLATE CYCLASE; IN-VIVO; MYOCARDIAL INFARCTION; SILICON NANOPARTICLES; TARGETING PEPTIDES;

POROUS SILICON;

10 UNDECENOIC ACID; ATRIAL NATRIURETIC FACTOR; INDIUM 111; ISOPRENALINE; NANOPARTICLE; NATRIURETIC PEPTIDE RECEPTOR A; SILICON; PEPTIDE; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC IMAGING; CARDIAC MUSCLE CELL; CELL STRUCTURE; CELL VIABILITY; CELLS BY BODY ANATOMY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; HEART; HEART DISEASE; HEART INFARCTION; IN VITRO STUDY; ISOTOPE LABELING; MALE; MUSCLE CELL; NONHUMAN; POROSITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TARGET ORGAN; ADSORPTION; ANIMAL; CELL SURVIVAL; CHEMISTRY; COLLOID; HUMAN; METABOLISM; PHYSIOLOGY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TEMPERATURE; ULTRASTRUCTURE; WISTAR RAT;

ADSORPTION; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PROTEINS; CELL SURVIVAL; COLLOIDS; HEART; HUMANS; MALE; MYOCYTES, CARDIAC; NANOPARTICLES; PEPTIDES; POROSITY; RATS, WISTAR; SILICON; TEMPERATURE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; UNDECYLENIC ACIDS;

EID: 84983113422     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.03.046     Document Type: Article

References (75)

1. World Health Organization Cardiovascular Diseases (CVDs) 2015, (accessed 02.04.15). http://wwwwhoint/mediacentre/factsheets/fs317/en/.
2. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., et al. Heart disease and stroke statistics-2015 update: a report from the american heart association. Circulation 2015, 131:e29-e322.
3. Dargie H. Heart failure post-myocardial infarction: a review of the issues. Heart 2005, 91:ii3-ii6.
4. Jessup M., Brozena S. Heart failure. N. Engl. J. Med. 2003, 348:2007-2018.
5. Linde C., Leclercq C., Rex S., Garrigue S., Lavergne T., Cazeau S., et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J. Am. Coll. Cardiol. 2002, 40:111-118.
6. Abraham W.T., Fisher W.G., Smith A.L., Delurgio D.B., Leon A.R., Loh E., et al. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. 2002, 346:1845-1853.
7. Rose E.A., Gelijns A.C., Moskowitz A.J., Heitjan D.F., Stevenson L.W., Dembitsky W., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 2001, 345:1435-1443.
8. Pascual-Gil S., Garbayo E., Diaz-Herraez P., Prosper F., Blanco-Prieto M.J. Heart regeneration after myocardial infarction using synthetic biomaterials. J. Control. Release 2015, 203:23-38.
9. Tan Y., Richards D., Xu R., Stewart-Clark S., Mani S.K., Borg T.K., et al. Silicon nanowire-induced maturation of cardiomyocytes derived from human induced pluripotent stem cells. Nano Lett. 2015, 15:2765-2772.
10. Blocki A., Beyer S., Dewavrin J.Y., Goralczyk A., Wang Y., Peh P., et al. Microcapsules engineered to support mesenchymal stem cell (MSC) survival and proliferation enable long-term retention of MSCs in infarcted myocardium. Biomaterials 2015, 53:12-24.
11. Miyagi Y., Zeng F., Huang X.P., Foltz W.D., Wu J., Mihic A., et al. Surgical ventricular restoration with a cell- and cytokine-seeded biodegradable scaffold. Biomaterials 2010, 31:7684-7694.
12. Ferreira M.P., Balasubramanian V., Hirvonen J., Ruskoaho H., Santos H.A. Advanced nanomedicines for the treatment and diagnosis of myocardial infarction and heart failure. Curr. Drug Targets 2015, 16:1682-1697.
13. Lam M.T., Wu J.C. Biomaterial applications in cardiovascular tissue repair and regeneration. Expert. Rev. Cardiovasc. Ther. 2012, 10:1039-1049.
14. Eniola-Adefeso O., Heslinga M.J., Porter T.M. Design of nanovectors for therapy and imaging of cardiovascular diseases. Methodist Debakey Cardiovasc. J. 2012, 8:13-17.
15. Shahbazi M.A., Hamidi M., Mäkilä E.M., Zhang H., Almeida P.V., Kaasalainen M., et al. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013, 34:7776-7789.
16. Secret E., Maynadier M., Gallud A., Gary-Bobo M., Chaix A., Belamie E., et al. Anionic porphyrin-grafted porous silicon nanoparticles for photodynamic therapy. Chem. Commun. 2013, 49:4202-4204.
17. Shen J., Wu X., Lee Y., Wolfram J., Yang Z., Mao Z.W., et al. Porous silicon microparticles for delivery of siRNA therapeutics. J. Vis. Exp. 2015, 95:52075.
18. Liu D., Mäkilä E.M., Zhang H., Herranz-Blanco B., Kaasalainen M., Kinnari P., et al. Nanostructured porous silicon-solid lipid nanocomposite: towards enhanced cytocompatibility and stability, reduced cellular association, and prolonged drug release. Adv. Funct. Mater. 2013, 23:1893-1902.
19. Tanaka T., Mangala L.S., Vivas-Mejia P.E., Nieves-Alicea R., Mann A.P., Mora E., et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010, 70:3687-3696.
20. Park J.H., Gu L., von Maltzahn G., Ruoslahti E., Bhatia S.N., Sailor M.J. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat. Mater. 2009, 8:331-336.
21. Tölli M.A., Ferreira M.P., Kinnunen S.M., Rysä J., Mäkilä E.M., Szabó Z., et al. In vivo biocompatibility of porous silicon biomaterials for drug delivery to the heart. Biomaterials 2014, 35:8394-8405.
22. Tasciotti E., Liu X., Bhavane R., Plant K., Leonard A.D., Price B.K., et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 2008, 3:151-157.
23. Tanaka T., Godin B., Bhavane R., Nieves-Alicea R., Gu J., Liu X., et al. In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int. J. Pharm. 2010, 402:190-197.
24. Salonen J., Laitinen L., Kaukonen A.M., Tuura J., Bjorkqvist M., Heikkilä T., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J. Control. Release 2005, 108:362-374.
25. Santos H.A., Hirvonen J. Nanostructured porous silicon materials: potential candidates for improving drug delivery. Nanomed. (Lond.) 2012, 7:1281-1284.
26. Herranz-Blanco B., Liu D., Mäkilä E.M., Shahbazi M.A., Ginestar E., Zhang H., et al. On-chip self-assembly of a smart hybrid nanocomposite for antitumoral applications. Adv. Funct. Mater. 2015, 25:1488-1497.
27. Osminkina L.A., Nikolaev A.L., Sviridov A.P., Andronova N.V., Tamarov K.P., Gongalsky M.B., et al. Porous silicon nanoparticles as efficient sensitizers for sonodynamic therapy of cancer. Microporous Mesoporous Mater. 2015, 210:169-175.
28. Shahbazi M.A., Shrestha N., Mäkilä E.M., Araújo F., Correia A., Ramos T., et al. A prospective cancer chemo-immunotherapy approach mediated by synergistic CD326 targeted porous silicon nanovectors. Nano Res. 2015, 8:1505-1521.
29. Araújo F., Shrestha N., Shahbazi M.A., Fonte P., Mäkilä E.M., Salonen J., et al. The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epithelium. Biomaterials 2014, 35:9199-9207.
30. Naveas N., Hernandez-Montelongo J., Pulido R., Torres-Costa V., Villanueva-Guerrero R., Predestinacion Garcia Ruiz J., et al. Fabrication and characterization of a chemically oxidized-nanostructured porous silicon based biosensor implementing orienting protein A. Colloids Surf. B. Biointerfaces 2014, 115:310-316.
31. Sosabowski J.K., Mather S.J. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Nat. Protoc. 2006, 1:972-976.
32. Wang C.F., Sarparanta M.P., Mäkilä E.M., Hyvönen M.L.K., Laakkonen P.M., Salonen J., et al. Multifunctional porous silicon nanoparticles for cancer theranostics. Biomaterials 2015, 48:108-118.
33. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol. Rev. 1992, 44:479-602.
34. Kato T., Muraski J., Chen Y., Tsujita Y., Wall J., Glembotski C.C., et al. Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt. J. Clin. Investig. 2005, 115:2716-2730.
35. Potter L.R., Yoder A.R., Flora D.R., Antos L.K., Dickey D.M. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb. Exp. Pharmacol. 2009, 191:341-366.
36. Nunez D.J.R., Dickson M.C., Brown M.J. Natriuretic peptide receptor messenger-RNAs in the rat and human heart. J. Clin. Investig. 1992, 90:1966-1971.
37. Lin X., Hänze J., Heese F., Sodmann R., Lang R.E. Gene expression of natriuretic peptide receptors in myocardial cells. Circ. Res. 1995, 77:750-758.
38. Cao L., Gardner D.G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995, 25:227-234.
39. Kanki S., Jaalouk D.E., Lee S., Yu A.Y., Gannon J., Lee R.T. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J. Mol. Cell. Cardiol. 2011, 50:841-848.
40. E. Ruoslahti, D. Mackenna, Heart homing peptides and methods of using same, US Patent #6303573 B1 October 16, 2001.
41. Xin M., Olson E.N., Bassel-Duby R. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. Nat. Rev. Mol. Cell. Biol. 2013, 14:529-541.
42. Gopi V., Subramanian V., Manivasagam S., Vellaichamy E. Angiotensin II down-regulates natriuretic peptide receptor-A expression and guanylyl cyclase activity in H9c2 (2-1) cardiac myoblast cells: role of ROS and NF-κB. Mol. Cell. Biochem. 2015, 409:67-79.
43. Ellison G.M., Torella D., Karakikes I., Purushothaman S., Curcio A., Gasparri C., et al. Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J. Biol. Chem. 2007, 282:11397-11409.
44. Bimbo L.M., Sarparanta M.P., Santos H.A., Airaksinen A.J., Mäkilä E.M., Laaksonen T., et al. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano 2010, 4:3023-3032.
45. Vengellur A., LaPres J.J. The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol. Sci. 2004, 82:638-646.
46. Wu D., Yotnda P. Induction and Testing of Hypoxia in Cell Culture. J. Vis. Exp. 2011, e2899.
47. Salonen J., Björkqvist M., Laine E., Niinistö L. Stabilization of porous silicon surface by thermal decomposition of acetylene. Appl. Surf. Sci. 2004, 225:389-394.
48. Cedervall T., Lynch I., Lindman S., Berggård T., Thulin E., Nilsson H., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. PNAS 2007, 104:2050-2055.
49. Patel H.M. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carr. Syst. 1992, 9:39-90.
50. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 2009, 61:428-437.
51. Kinnari P., Hyvönen M.L., Mäkilä E.M., Kaasalainen M.H., Rivinoja A., Salonen J., et al. Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy. Biomaterials 2013, 34:9134-9141.
52. Monopoli M.P., Walczyk D., Campbell A., Elia G., Lynch I., Baldelli Bombelli F., et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 2011, 133:2525-2534.
53. Shahbazi M.A., Almeida P.V., Mäkilä E.M., Kaasalainen M., Salonen J., Hirvonen J., et al. Augmented cellular trafficking and endosomal escape of porous silicon nanoparticles via zwitterionic bilayer polymer surface engineering. Biomaterials 2014, 35:7488-7500.
54. Santos H.A., Riikonen J., Salonen J., Mäkilä E.M., Heikkilä T., Laaksonen T., et al. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater. 2010, 6:2721-2731.
55. Leroueil P.R., Hong S., Mecke A., Baker J.R., Orr B.G., Banaszak Holl M.M. Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face?. Acc. Chem. Res. 2007, 40:335-342.
56. Verma A., Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 2010, 6:12-21.
57. Gaihre B., Hee Lee Y., Seob Khil M., Keun Yi H., Yong Kim H. In-vitro cytotoxicity and cell uptake study of gelatin-coated magnetic iron oxide nanoparticles. J. Microencapsul. 2011, 28:240-247.
58. Deol S., Weerasuriya N., Shon Y.S. Stability, cytotoxicity and cell uptake of water-soluble dendron-conjugated gold nanoparticles with 3, 12 and 17 nm cores. J. Mater. Chem. B 2015, 3:6071-6080.
59. Bhattacharjee S., Ershov D., Fytianos K., van der Gucht J., Alink G.M., Rietjens I.M.C.M., et al. Cytotoxicity and cellular uptake of tri-block copolymer nanoparticles with different size and surface characteristics. Part. Fibre. Toxicol. 2012, 9:1-19.
60. Verena H., Myriam L., Clemens Kilian W., Hubert S., Katharina L., Volker M. Synthesis and biomedical applications of functionalized fluorescent and magnetic dual reporter nanoparticles as obtained in the miniemulsion process. J. Phys. Condens. Matter 2006, 18:S2581.
61. Guarnieri D., Malvindi M., Belli V., Pompa P., Netti P. Effect of silica nanoparticles with variable size and surface functionalization on human endothelial cell viability and angiogenic activity. J. Nanopart. Res. 2014, 16:1-14.
62. Ryman-Rasmussen J.P., Riviere J.E., Monteiro-Riviere N.A. Variables influencing interactions of untargeted quantum dot nanoparticles with skin cells and identification of biochemical modulators. Nano Lett. 2007, 7:1344-1348.
63. Zaitseva K.V., Varfolomeev M.A., Novikov V.B., Solomonov B.N. Enthalpy of cooperative hydrogen bonding in complexes of tertiary amines with aliphatic alcohols: calorimetric study. J. Org. Chem. 2011, 43:1083-1090.
64. Rytkönen J., Miettinen R., Kaasalainen M., Lehto V.P., Salonen J., Närvänen A. Functionalization of mesoporous silicon nanoparticles for targeting and bioimaging purposes. J. Nanomater. 2012, 2012:1-9.
65. Nerbonne J.M., Kass R.S. Molecular physiology of cardiac repolarization. Physiol. Rev. 2005, 85:1205-1253.
66. Savi M., Rossi S., Bocchi L., Gennaccaro L., Cacciani F., Perotti A., et al. Titanium dioxide nanoparticles promote arrhythmias via a direct interaction with rat cardiac tissue. Part. Fibre. Toxicol. 2014, 11:63.
67. Miragoli M., Novak P., Ruenraroengsak P., Shevchuk A.I., Korchev Y.E., Lab M.J., et al. Functional interaction between charged nanoparticles and cardiac tissue: a new paradigm for cardiac arrhythmia?. Nanomedicine 2012, 8:725-737.
68. Gallo S., Gatti S., Sala V., Albano R., Costelli P., Casanova E., et al. Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. Cell Death Dis. 2014, 5:e1185.
69. Jin H., Heller D.A., Sharma R., Strano M.S. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano 2009, 3:149-158.
70. Yang C., Uertz J., Yohan D., Chithrani B.D. Peptide modified gold nanoparticles for improved cellular uptake, nuclear transport, and intracellular retention. Nanoscale 2014, 6:12026-12033.
71. Tkachenko A.G., Xie H., Liu Y., Coleman D., Ryan J., Glomm W.R., et al. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 2004, 15:482-490.
72. Moro C., Galitzky J., Sengenes C., Crampes F., Lafontan M., Berlan M. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat cells. J. Pharmacol. Exp. Ther. 2004, 308:984-992.
73. Wyss D.F., Lahm H.W., Manneberg M., Labhardt A.M. Anantin-a peptide antagonist of the atrial natriuretic factor (ANF). II. Determination of the primary sequence by NMR on the basis of proton assignments. J. Antibiot. 1991, 44:172-180.
74. Trachte G.J. Atrial natriuretic factor alters neurotransmission independently of guanylate cyclase-coupled receptors in the rabbit vas deferens. J. Pharmacol. Exp. Ther. 1993, 264:1227-1233.
75. Yildirimer L., Thanh N.T.K., Loizidou M., Seifalian A.M. Toxicology and clinical potential of nanoparticles. Nano Today 2011, 6:585-607.